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A Cross-Cohort Study Examining the Associations of Metabolomic
Proﬁle and Subclinical Atherosclerosis in Children and Their Parents:
The Child Health CheckPoint Study and Avon Longitudinal Study of
Parents and Children
Markus Juonala, MD, PhD; Susan Ellul, MBiostat; Debbie A. Lawlor, MBChB, MSc, PhD; Diana L. Santos Ferreira, PhD; John B. Carlin, PhD;
Michael Cheung, MD; Terence Dwyer, MD, MPH; Melissa Wake, MD;* Richard Saffery, PhD;* David P. Burgner, MD, PhD;*
Background-—High-throughput nuclear magnetic resonance proﬁling of circulating metabolites is suggested as an adjunct for
cardiovascular risk evaluation. The relationship between metabolites and subclinical atherosclerosis remains unclear, particularly
among children. Therefore, we examined the associations of metabolites with carotid intima-media thickness (cIMT) and arterial
pulse wave velocity (PWV).
Methods and Results-—Data from two independent population-based studies was examined; (1) cross-sectional associations with
cIMT and PWV in 1178 children (age 11–12 years, 51% female) and 1316 parents (mean age 45 years, 87% female) from the
CheckPoint study (Australia); and (2) longitudinal associations in 4249 children (metabolites at 7–8 years, PWV at 10–11 years,
52% female), and cross-sectional associations in 4171 of their mothers (mean age 48 years, cIMT data) from ALSPAC (The Avon
Longitudinal Study of Parents and Children; UK). Metabolites were measured by the same nuclear magnetic resonance platform in
both studies, comprising of 69 biomarkers. Biophysical assessments included body mass index, blood pressure, cIMT and PWV. In
linear regression analyses adjusted for age, sex, body mass index, and blood pressure, there was no evidence of metabolite
associations in either children or adults for cIMT at a 10% false discovery threshold. In CheckPoint adults, glucose was positively,
and some high-density lipoprotein-cholesterol derived measures and amino acids (glutamine, histidine, tyrosine) inversely
associated with PWV.
Conclusions-—These data suggest that in children circulating metabolites have no consistent association with cIMT and PWV once
adjusted for body mass index and blood pressure. In their middle-aged parents, some evidence of metabolite associations with
PWV were identiﬁed that warrant further investigation. ( J Am Heart Assoc. 2019;8:e011852. DOI: 10.1161/JAHA.118.
011852.)
Key Words: intima-media thickness • pediatric • pulse wave velocity
A therosclerotic cardiovascular disease (CVD) is the lead-ing cause of mortality worldwide. Although its clinical
complications usually become evident only from midlife,
atherosclerosis has its origins in early life.1 Traditional risk
factors in childhood, including dyslipidemia, elevated blood
pressure (BP), tobacco smoke exposure, diabetes mellitus,
and obesity, are associated with vascular phenotypes indica-
tive of subclinical atherosclerosis and subsequent risk of
CVD.2–5 However, the ﬁrst clinical CVD events often occur
among adults without traditional risk factors who would be
classiﬁed as being at low or intermediate risk based on widely
used CVD risk algorithms.6
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There has been increasing interest in the potential of the
metabolic proﬁle (metabolomics) to reveal both novel
insights into pathophysiology and contribute to improved
clinical prediction of atherosclerotic CVD.7,8 Nuclear mag-
netic resonance (NMR) methodology enables the rapid,
inexpensive, and reproducible quantiﬁcation of circulating
lipids and metabolites, including several amino acids,
glycolysis-related metabolites, and ketone bodies.9 In
adults, distinct metabolomic proﬁles have been shown to
predict all-cause mortality, cardiovascular events, and type
2 diabetes mellitus.7,8,10 However, there are a paucity of
equivalent data for early subclinical markers of atheroscle-
rosis, especially in childhood.
In the present study, we ﬁrst investigated the age- and sex-
adjusted associations of NMR metabolomic proﬁle with
measures of subclinical atherosclerosis, carotid intima-media
thickness (cIMT), and arterial pulse-wave velocity (PWV) in
children and their mothers. We then investigated these
associations with additional adjustment for body mass index
(BMI) and systolic BP, to determine whether the NMR
metabolomic proﬁle has the potential to improve risk
prediction over and above these established risk factors that
are readily accessible to both clinical and public health
settings. These vascular measures are widely used in
epidemiological studies, given that they are associated with
cardiovascular risk factors and independently predict cardio-
vascular events in adults.4,5
Methods
We utilized data from the Child Health CheckPoint study
(“CheckPoint”) and ALSPAC (The Avon Longitudinal Study of
Parents and Children).
CheckPoint was a detailed cross-sectional assessment of
physical health and biomarkers in a population-based national
sample of Australian children (aged 11–12 years) and 1 of
their parents, conducted between February 2015 and March
2016.11,12 CheckPoint is a substudy nested between waves 6
(2014) and 7 (2016) of data collection in the Longitudinal
Study of Australian Children (LSAC), which recruited a
nationally representative sample of 5107 (57.2% uptake) 0-
to 1-year-old infants in 2004 and has since followed them
biennially.13 The CheckPoint study population included here
consisted of 1178 children (mean age, 12.0 years; 51.0%
females) and 1316 adults (mean age, 44.6 years; 86.6%
females, predominantly the child’s mother) with metabolo-
mics, cIMT, and/or PWV measurements available (Figure 1).
The protocol was approved by The Royal Children’s Hospital
(Melbourne, Australia) Human Research Ethics Committee
and the Australian Institute of Family Studies Ethics Commit-
tee. The attending parent/caregiver gave written informed
consent for themselves and their child, and optional consent
for the collection and analysis of biological samples.
ALSPAC is a prospective, population-based birth cohort
study that recruited 14 541 pregnant women resident in the
South West of England with expected dates of delivery
between April 1, 1991 and December 31, 1992. These
women, their partners, and their offspring have been followed
up for 28 years with repeat questionnaires, hands-on clinic
assessments, and record-linkage, with full details of the study
published elsewhere.14,15 For the current study, we used data
from 4249 offspring who had metabolites measured at age 7
to 8 years and arterial PWV measured at age 11 to 12 years,
together with 4171 mothers who had metabolites and cIMT
measured cross-sectionally at mean age 48 years (Figure 1).
These assessment time points were selected to be as close as
possible to those of the CheckPoint children and parents.
Ethical approval for the study was obtained from the ALSPAC
Ethics and Law Committee and from the UK NHS National
Health Service Local Research Ethics Committees. Partici-
pants have provided informed consent for the use of the data,
with the main caregiver (most commonly their mother)
providing consent for their child and the child providing
assent to any speciﬁc data collection or blood sampling.
Clinical Perspective
What Is New?
• The analyses of two large independent population-based
studies (CheckPoint, ALSPAC [The Avon Longitudinal Study
of Parents and Children]) revealed limited evidence of an
association between nuclear magnetic resonance–based
metabolomic proﬁle and subclinical phenotypes of
atherosclerosis in children following adjustment for age
and sex.
• These associations were generally attenuated toward the
null with further adjustment for body mass index and
systolic blood pressure.
• In the CheckPoint adults, but not CheckPoint or ALSPAC
children, glucose was positively and some high-density
lipoprotein-cholesterol derived measures and amino acids
(glutamine, histidine and tyrosine) were inversely associated
with pulse wave velocity independently of body mass index
and systolic blood pressure.
What Are the Clinical Implications?
• Our ﬁndings from general populations do not support
introduction of nuclear magnetic resonance metabolic
proﬁles into pediatric cardiovascular practice.
• Among adults we observed some signals related to preclin-
ical atherosclerosis, but the most robust evidence to date
with this nuclear magnetic resonance platform comes from
prospective analyses with disease endpoints and replication
across three independent cohorts.
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Metabolomics
In CheckPoint, semifasted (median, 4.2 hours postprandial)
peripheral blood was collected and processed within 4 hours
at an on-site processing laboratory, with serum aliquots frozen
at 80°C for batch analysis.12,16 In the ALSPAC, nonfasted
peripheral blood was collected in children and fasted (over-
night or minimum 6 hours) in mothers; in both, samples were
Attended 
Focus@7: 
n=8300 (1998-2000)
Children alive at 1 year of 
age 
n=13971
- 825 not eligible
Eligible to attend clinical 
assessment at the age of 7 
years (Focus@7)
n=13146
-3483 did not respond 
-976 did not want to attend
-806 failed to attend the appointment
-2 children were ill on the appointment day
-35 willing to come but were unable to attend
+ 456 new children recruited from 452 pregnancies
Metabolic profiling of 
EDTA-plasma samples (by 
Nuclear Magnetic 
Resonance)
n=5527 
n= 4249 children
2773 without metabolic profile
1278 without data on exposure and/or 
covariates
Clinical assessment: 
n=11264 invited to Focus 
on Mothers 1 (FoM1)
n=4834 (43% of invited) 
attended
-343 without metabolic profile
-136 women enrolled in more then one 
pregnancy
Metabolic profiling of 
EDTA-plasma samples (by 
Nuclear Magnetic 
Resonance)
n=4355
184 without data on exposure and/or 
covariates
n= 4171 women
Recruited pregnancy 
cohort
n=14541 women
Of which 674 excluded: 
-69 unknown outcomes 
-604 no live-birth 
-1 live-birth only from a twin pregnancy
Included pregnancy cohort 
n = 13867
Included individual women 
n = 13761
-Including 106 sib-ships
A
B C
Figure 1. Flow charts of CheckPoint and ALSPAC (The Avon Longitudinal Study of Parents and Children) studies. A,
CheckPoint, (B) ALSPAC children, and (C) ALSPAC adults. LSAC indicates Longitudinal Study of Australian Children.
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processed within 4 hours and stored at 80°C.17,18 Metabo-
lomic proﬁling9,16 was done using the Nightingale NMR
metabolomics platform (Helsinki, Finland), and 228 metabolic
traits (or their ratios) were quantiﬁed in serum (CheckPoint) or
EDTA-plasma (ALSPAC). With this platform, the coefﬁcients of
variation for the metabolomics variables in the present study
vary between 1.5% and 12.5%, with very large very-low-density
lipoprotein (12.5%), very large high-density lipoprotein (HDL;
10.6%), and citrate (10.1%) being the only variables having
coefﬁcients of variation over 10%.19 In present cohorts for
most variables, data were available in >99% of participants.
Many of these metabolomics measures correlate substantially
both in adults and children.16,20 For clarity and in line with
earlier research with this platform,21 we therefore focused on
69 lipids and metabolites in this study. We excluded the 5
ratio measures for each of the 14 lipoprotein subclass
particles. In addition, the 7 other measures within each of the
lipoproteins (esteriﬁed cholesterol, free cholesterol, total
cholesterol, triglycerides, phospholipids, total lipids, and
particle concentration) are derived from other metabolites
and all highly correlated. Therefore, we only reported total
lipids for each of the lipoprotein subclass particles. Glyco-
protein acetyl was excluded given that it has been analyzed in
another report. We excluded glycerol, glycine, and pyruvate
because they were only quantiﬁed for CheckPoint and not the
ALSPAC because of differences in the sample types (plasma
versus serum) analyzed.
Age, Sex, BMI, BP, and Socioeconomic Status
In CheckPoint, children’s date of birth and sex were from
LSAC records. In adults, self-reported sex and date of birth
were acquired at time of assessment. Trained assessors
measured participant’s height using a Leicester height meter,
without shoes and in light clothing, to the nearest 0.1 cm, in
duplicate. A third measurement was taken if the difference of
the ﬁrst 2 measurements was >0.5 cm. The mean of all
measurements was used in analyses. An InBody230 bioelec-
trical impedance analysis scale (Biospace Co. Ltd., Seoul,
South Korea) measured weight to the nearest 0.1 kg. Body
mass index (BMI) was calculated by dividing the weight (kg) by
the height squared (m2). Supine brachial artery BP was
measured after a 7-minute rest up to 3 times using the
SphygmoCor XCEL (AtCor Medical Pty Ltd., West Ryde, NSW,
Australia), and the mean values were used in analysis.
Parental education data were obtained from questionnaires
and categorized into 3 groups: tertiary educated, completed
high school (year 12) only, or completed less than year 12.
In ALSPAC children, sex and birthdate were recorded in the
delivery room and abstracted from obstetric records and/or
birth notiﬁcations. Exact age was determined from the child’s
date of birth and date of the examination. Weight (to the
nearest 0.1 kg), using seca scales (seca, Hamburg, Germany),
and height (to the nearest 0.1 cm), using a Leicester height
meter, were both measured with the child unshod and in light
clothing at age 7 years (at the time of metabolite measure-
ment). BMI was calculated as in CheckPoint. Seated BP was
also measured at age 7 years with the child at rest, their arm
supported, and the correct cuff size (after measurement of
arm circumference), using an Omron M6 upper arm monitor
(Omron Healthcare, Inc., Lake Forest, IL). In ALSPAC mothers
at mean age 48 years, weight was measured to the nearest
0.1 kg using Tanita scales (Tanita Corporation, Tokyo, Japan);
height was measured to the nearest 0.1 cm using a
Harpenden stadiometer (women were unshod and in light
clothing). Seated BP was measured with the woman at rest,
her arm supported and the correct cuff size (after measure-
ment of arm circumference), using an Omron M6 upper arm
monitor (Omron Healthcare, Inc.,). The mean of 2 BP
measurements were used in children and adults. Maternal
education was obtained from questionnaires and categorized
into 3 groups: university degree or above, A-level (Advanced
Level; exams taken in different subjects usually at age 18
years), or below A-level.
Vascular Phenotypes
Carotid intima-media thickness
In CheckPoint, cIMT was measured as previously described.22
B-mode ultrasound carotid artery images were acquired using
standardized protocols. cIMT was measured 10 mm prox-
imal to the carotid bulb, over a distance of 5 to 10 mm.
Participants lay supine with their head turned 45 degrees to
the left to expose the right side of the neck. A 10-MHz linear
array probe (Vivid-I; GE Healthcare, Chicago, IL) obtained cine
loops of the right common carotid artery, in triplicate.
Modiﬁed 3-lead ECG captured cardiac cycle information
concurrently. All images were transferred to digital storage
for archiving. Six raters measured cIMT in the ultrasound
images using software available in Carotid Analyzer (Medical
Imaging Applications, Coralville, IA). The within- and between-
observer coefﬁcients of variation were 4.9% and 6.2%,
respectively.22
In the ALSPAC, mothers’ cIMT measurements were
acquired from both the left and right common carotid artery
arteries, using high-resolution B-ultrasound and scanning
longitudinally 1 cm proximal to the carotid bifurcation follow-
ing a standardized protocol. A Zonare Z One Ultra convertible
ultrasound system with an L10-5 linear transducer was used.
Images were focused on the posterior (far) wall of the artery,
and the zoom function was used to magnify the area. Ten-
second cine loops were recorded in DICOM format and
analyzed ofﬂine using Carotid Analyzer for Research (Vascular
Research Tools 5; Medical Imaging Applications, LLC,
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Coralville, IA). Three consecutive cardiac cycles were identi-
ﬁed, and 3 measures of cIMT were taken from end-diastolic
frames and averaged. This was done for both right and left
carotid arteries. The mean of the left- and right-sided readings
was used in all analyses. Images were analyzed by a single
trained reader. cIMT was not measured in the offspring during
childhood.
Pulse Wave Velocity
In CheckPoint, carotid-femoral PWV was determined using the
SphygmoCor XCEL (AtCor Medical, Sydney, NSW, Australia).23
After a 7-minute rest, assessors obtained velocity (distance/
time) measurements 1 to 3 times while participants lay
supine. Further analyses used the mean of the measurements.
Simultaneously recorded carotid waveform, using tonometric
applanation, and a femoral waveform, using a cuff placed
around the upper thigh inﬂated to subdiastolic pressure,
provided the time component of PWV. A tape measure was
used to record the distance from the carotid pulse to the
suprasternal notch to right femoral pulse (estimated by the
crease between thigh and torso when the knee was bent to
90 degrees) to the top of the thigh cuff.
In the ALSPAC, offspring PWV was assessed using
applanation tonometry at age 10. Pressure-pulse waveforms
were recorded transcutaneously using a high-ﬁdelity micro-
manometer (SPC-301; Millar Instruments, Houston, TX) from
the radial and carotid pulse synchronous with the ECG signal,
which provides an R-timing reference. Integral software
processed the data to calculate the mean time difference
between R-wave and pressure wave on a beat-to-beat basis
over 10 seconds, and the PWV was then calculated using the
mean time difference and arterial path length between the 2
recording points (SphygmoCorversion 7.1; ScanMed Medical,
Moreton-in-Marsh, UK).24 PWV was not measured in ALSPAC
mothers.
Statistical Analysis
To describe the study participants, continuous variables were
presented as mean (SD) for continuous variables and as
number (%) for categorical variables. Because of differences in
units and distributions of metabolite measures, metabolite
concentrations were scaled to SD units separately for children
and adults in each cohort to make comparisons across
measures more meaningful. The correlation between parent-
child metabolite levels was estimated using Spearman’s
correlation coefﬁcients.
Linear regression models were ﬁtted separately for
CheckPoint and ALSPAC children and parents with each
metabolite concentration as the explanatory variable and
cIMT (CheckPoint children and parents, ALSPAC mothers) and
PWV (CheckPoint children and parents, ALSPAC children) as
the outcomes. Coefﬁcients are presented as difference in
mean cIMT (mm) or PWV (m/s) per 1-SD unit increase in
metabolite concentration, with 95% conﬁdence intervals.
Associations were initially adjusted for age and sex, known
to impact speciﬁc metabolite levels, and then additionally for
BMI and systolic BP given that these are previously described
risk factors associated with cIMT and PWV2,25 P values were
adjusted using the method of Benjamini–Hochberg with a
false discovery rate of 10% to account for the number of
metabolites examined.26
Analysis was performed using Stata (version 15.1;
StataCorp LP, College Station, TX) and R software (version
3.5.0; R Foundation for Statistical Computing, Vienna,
Austria).
Results
Characteristics of the participants in both cohorts are shown
in Table 1 and mean metabolite levels in Table 2. Parent-child
correlations of metabolite levels in both cohorts are shown in
Figure 2.
Metabolomic Measures and cIMT
There was no replication of any statistically signiﬁcant
associations across ages or cohorts. In age- and sex-adjusted
analyses, citrate was positively associated with cIMT in
CheckPoint children, mean diameter of very-low-density
lipoprotein–related particles and phenylalanine were posi-
tively and HDL-related measures, apolipoprotein A-1, and fatty
acid ratios inversely associated with cIMT in CheckPoint
adults (Figure 3). In ALSPAC adults, there was no evidence of
an association between any metabolite measure and cIMT. In
both ages and both cohorts, associations of metabolic
measures with cIMT attenuated toward null following addi-
tional adjustment for BMI and systolic BP (Figure 4).
Metabolomic Measures and PWV
Results from age- and sex-adjusted analyses are shown in
Figure 5. Very-low-density lipoprotein– and triglyceride-
derived measures, apolipoprotein B, and several fatty acids
were positively and HDL-related measures, apolipoprotein A-I,
and glutamine inversely associated with PWV in CheckPoint
children and adults. Valine was positively associated with
PWV in CheckPoint children, whereas glucose, lactate,
isoleucine, leucine, and phenylalanine were positively and
histidine and creatinine inversely related with PWV in
CheckPoint adults. In ALSPAC children, there was no evidence
of an association between any metabolite and PWV. With
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further adjustment for BMI and systolic BP (Figure 6), all
associations attenuated to the null in CheckPoint children. In
CheckPoint adults, glucose and the amount of total lipids in
small HDL were positively and total lipids in very large HDL,
mean diameter of HDL, glutamine, histidine, and tyrosine were
inversely associated with PWV.
Discussion
Our analyses of 2 large, independent, population-based
studies revealed limited evidence of an association between
NMR-based metabolomic proﬁle and subclinical phenotypes
of atherosclerosis in children following adjustment for age and
sex. These associations were generally attenuated toward the
null with further adjustment for BMI and systolic BP. In the
CheckPoint adults, but not CheckPoint or ALSPAC children,
glucose was positively and some HDL-cholesterol derived
measures and amino acids (glutamine, histidine, and tyrosine)
were inversely associated with PWV independently of BMI and
systolic BP.
We were unable to identify other published studies of the
associations of multiple metabolites with cIMT or PWV in
children. Several studies in adults have shown associations
with cardiovascular events. For example, a previous study of 3
independent adult cohorts from Finland and the UK (total
N=13 441) found robust (replicated), prospective associa-
tions between NMR-derived measures (using the same NMR
platform as here) and cardiovascular events, even with
adjustment for conventional risk factors (age, sex, lipids, BP,
smoking, diabetes mellitus, and medication).27 Speciﬁcally,
phenylalanine and monounsaturated fatty acids were posi-
tively associated with subsequent CVD event risk, whereas
omega-6 fatty acids and docosahexaenoic acid levels were
inversely associated.27 Furthermore, a systematic review of
prospective studies reported evidence of associations of
multiple metabolites with CVD.8 Given these existing ﬁndings
and evidence that the arterial antecedents of CVD begin in
childhood, we hypothesized that multiple metabolites would be
associated with measures of arterial disease in children.
However, we found no evidence for this in our cross-sectional
and relatively short (3-year follow-up) longitudinal analyses. This
may indicate that a longer exposure period to adverse metabo-
lite levels is needed to observe an association with the
subclinical vascular phenotypes. It is also important to consider
Table1. Characteristics of the Study Cohort
Characteristic
Children Adults
N Mean (SD)* N Mean (SD)*
CheckPoint (Australia)
Age, y 1178 12.0 (0.4) 1316 44.6 (5.2)
Male, % 1178 575 (48.8) 1316 177 (13.5)
BMI, kg/m2 1177 19.2 (3.3) 1312 27.8 (6.0)
Mean systolic BP, mmHg 1002 108 (8) 1200 121 (13)
Mean cIMT, mm 1170 0.50 (0.06) 1294 0.57 (0.08)
Arterial pulse-wave velocity, m/s† 1141 4.44 (0.55) 1184 6.96 (1.12)
Education, % (< year 12/year 12/tertiary education) 1174 20/43/37
ALSPAC (UK)
Age at exposure assessment, y 4249 7.5 (0.3) 4171 47.9 (4.4)
Age at outcome assessment, y 4249 10.6 (0.2) 4171 47.9 (4.4)
Male, % 4249 2156 (51) 4171 0 (0)
BMI, kg/m2 4249 16.2 (1.9) 4171 26.5 (5.2)
Mean systolic BP, mmHg 4249 98 (9) 4171 118 (12)
Mean cIMT, mm 4171 0.56 (0.06)
Arterial pulse-wave velocity, m/s‡ 4249 7.53 (1.21)
Education, % (< A-level§/A-level/university degree or above) 3883 52/29/19
ALSPAC indicates The Avon Longitudinal Study of Parents and Children; BMI, body mass index; BP, blood pressure; cIMT, carotid intima-media thickness.
*Mean (SD) for normally distributed variables, n (%) for categorical variables.
†
Carotid-femoral pulse-wave velocity.
‡
Carotid-radial pulse wave velocity.
§
Advanced level; exams taken in different subjects usually at age 18years.
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Table 2. Mean Metabolite Levels in Children and Parents in Study Cohorts
Metabolite
CheckPoint ALSPAC
Children Parents Children Parents (Mothers)
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Lipoprotein subclass lipids
Total lipids in chylomicrons and ex.large VLDL, mmol/L 0.03 (0.03) 0.04 (0.04) 0.03 (0.02) 0.02 (0.02)
Total lipids in very large VLDL, mmol/L 0.06 (0.07) 0.08 (0.10) 0.06 (0.06) 0.04 (0.06)
Total lipids in large VLDL, mmol/L 0.22 (0.21) 0.295 (0.30) 0.19 (0.16) 0.17 (0.20)
Total lipids in medium VLDL, mmol/L 0.45 (0.27) 0.56 (0.40) 0.41 (0.20) 0.41 (0.29)
Total lipids in small VLDL, mmol/L 0.39 (0.15) 0.50 (0.22) 0.53 (0.12) 0.55 (0.21)
Total lipids in very small VLDL, mmol/L 0.33 (0.07) 0.43 (0.11) 0.48 (0.07) 0.54 (0.12)
Total lipids in IDL, mmol/L 0.82 (0.18) 1.00 (0.24) 0.94 (0.18) 1.12 (0.27)
Total lipids in large LDL, mmol/L 0.94 (0.23) 1.16 (0.29) 1.00 (0.22) 1.23 (0.34)
Total lipids in medium LDL, mmol/L 0.52 (0.14) 0.66 (0.18) 0.54 (0.14) 0.69 (0.21)
Total lipids in small LDL, mmol/L 0.34 (0.09) 0.43 (0.11) 0.36 (0.09) 0.45 (0.13)
Total lipids in very large HDL, mmol/L 0.50 (0.19) 0.50 (0.24) 0.61 (0.14) 0.55 (0.23)
Total lipids in large HDL, mmol/L 0.87 (0.28) 0.89 (0.41) 0.79 (0.17) 1.00 (0.35)
Total lipids in medium HDL, mmol/L 0.89 (0.13) 0.96 (0.18) 0.82 (0.09) 1.03 (0.15)
Total lipids in small HDL, mmol/L 1.01 (0.12) 1.08 (0.15) 1.00 (0.07) 1.12 (0.12)
Lipoprotein particle size
Mean diameter for VLDL particles, nm 37.07 (1.58) 36.97 (1.68) 36.46 (1.29) 35.78 (1.31)
Mean diameter for LDL particles, nm 23.61 (0.11) 23.56 (0.10) 23.64 (0.10) 23.62 (0.11)
Mean diameter for HDL particles, nm 10.10 (0.23) 10.06 (0.28) 10.07 (0.15) 10.10 (0.24)
Cholesterol
Serum total cholesterol, mmol/L 3.60 (0.63) 4.26 (0.82) 3.94 (0.60) 4.64 (0.86)
Total cholesterol in VLDL, mmol/L 0.45 (0.18) 0.60 (0.28) 0.63 (0.16) 0.67 (0.24)
Remnant cholesterol (non-HDL, non-LDL cholesterol), mmol/L 0.97 (0.27) 1.23 (0.38) 1.22 (0.24) 1.38 (0.39)
Total cholesterol in LDL, mmol/L 1.15 (0.34) 1.47 (0.44) 1.23 (0.33) 1.56 (0.50)
Total cholesterol in HDL, mmol/L 1.49 (0.27) 1.56 (0.38) 1.49 (0.21) 1.70 (0.32)
Total cholesterol in HDL2, mmol/L 1.02 (0.25) 1.07 (0.35) 0.89 (0.14) 1.15 (0.29)
Total cholesterol in HDL3, mmol/L 0.47 (0.02) 0.48 (0.03) 0.60 (0.07) 0.55 (0.04)
Esterified cholesterol, mmol/L 2.53 (0.46) 2.99 (0.59) 2.78 (0.43) 3.27 (0.62)
Free cholesterol, mmol/L 1.08 (0.18) 1.27 (0.24) 1.17 (0.18) 1.36 (0.25)
Glycerides and phospholipids
Serum total triglycerides, mmol/L 1.02 (0.46) 1.28 (0.69) 1.05 (0.38) 1.06 (0.54)
Triglycerides in VLDL, mmol/L 0.70 (0.43) 0.87 (0.63) 0.69 (0.33) 0.64 (0.45)
Triglycerides in LDL, mmol/L 0.118 (0.026) 0.16 (0.04) 0.145 (0.048) 0.17 (0.06)
Triglycerides in HDL, mmol/L 0.132 (0.029) 0.15 (0.04) 0.113 (0.021) 0.138 (0.035)
Total phosphoglycerides, mmol/L 1.63 (0.25) 1.93 (0.34) 1.77 (0.27) 1.94 (0.35)
Ratio of triglycerides to phosphoglycerides 0.54 (0.27) 0.59 (0.32) 0.52 (0.21) 0.46 (0.20)
Phosphatidylcholine and other cholines, mmol/L 1.69 (0.25) 1.98 (0.33) 1.84 (0.27) 2.03 (0.35)
Total cholines, mmol/L 2.00 (0.26) 2.32 (0.35) 2.17 (0.30) 2.35 (0.37)
Apolipoproteins
Apolipoprotein A1, g/L 1.50 (0.16) 1.59 (0.21) 1.48 (0.11) 1.69 (0.17)
Apolipoprotein B, g/L 0.69 (0.13) 0.82 (0.19) 0.73 (0.12) 0.86 (0.20)
Continued
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Table 2. Continued
Metabolite
CheckPoint ALSPAC
Children Parents Children Parents (Mothers)
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Ratio of apolipoprotein B to apolipoprotein A-I 0.47 (0.10) 0.52 (0.14) 0.49 (0.09) 0.51 (0.13)
Fatty acids
Total fatty acids, mmol/L 9.25 (1.65) 10.98 (2.38) 10.24 (1.61) 11.13 (2.17)
Estimated degree of unsaturation 1.21 (0.06) 1.21 (0.06) 1.16 (0.06) 1.21 (0.06)
22:6, docosahexaenoic acid, mmol/L 0.08 (0.03) 0.11 (0.04) 0.11 (0.03) 0.15 (0.05)
18:2, linoleic acid, mmol/L 2.56 (0.46) 2.89 (0.56) 2.83 (0.44) 2.93 (0.54)
Omega-3 fatty acids, mmol/L 0.30 (0.08) 0.40 (0.12) 0.33 (0.07) 0.44 (0.12)
Omega-6 fatty acids, mmol/L 3.08 (0.49) 3.52 (0.61) 3.43 (0.49) 3.71 (0.63)
Polyunsat. fatty acids, mmol/L 3.38 (0.55) 3.93 (0.70) 3.76 (0.54) 4.15 (0.70)
Monounsat. fatty acids; 16:1, 18:1, mmol/L 2.52 (0.62) 3.09 (0.93) 2.39 (0.57) 2.82 (0.80)
Saturated fatty acids, mmol/L 3.35 (0.64) 3.96 (0.93) 4.08 (0.67) 4.16 (0.82)
Fatty acid ratios
Ratio of 22:6 docosahexaenoic acid to total fatty acids (%) 0.83 (0.25) 1.03 (0.28) 1.07 (0.22) 1.32 (0.35)
Ratio of 18:2 linoleic acid to total fatty acids (%) 27.81 (3.24) 26.66 (3.43) 27.75 (2.41) 26.48 (2.80)
Ratio of omega-3 fatty acids to total fatty acids (%) 3.27 (0.59) 3.70 (0.71) 3.25 (0.52) 3.97 (0.85)
Ratio of omega-6 fatty acids to total fatty acids (%) 33.55 (3.11) 32.48 (3.37) 33.68 (2.62) 33.56 (2.64)
Ratio of polyunsat. fatty acids to total fatty acids (%) 36.82 (3.35) 36.18 (3.62) 36.94 (2.75) 37.53 (2.83)
Ratio of monounsat. fatty acids to total fatty acids (%) 26.99 (2.61) 27.81 (2.90) 23.21 (2.72) 25.07 (2.88)
Ratio of saturated fatty acids to total fatty acids (%) 36.19 (1.74) 36.00 (1.96) 39.86 (1.77) 37.39 (1.56)
Glycolysis related
Glucose, mmol/L 3.86 (0.64) 3.88 (0.85) 4.18 (0.52) 4.48 (0.88)
Lactate, mmol/L 1.73 (0.46) 1.56 (0.46) 1.36 (0.48) 0.80 (0.34)
Citrate, mmol/L 0.13 (0.02) 0.11 (0.02) 0.13 (0.03) 0.094 (0.03)
Amino acids
Alanine, mmol/L 0.39 (0.06) 0.40 (0.06) 0.29 (0.06) 0.25 (0.06)
Glutamine, mmol/L 0.48 (0.05) 0.46 (0.07) 0.54 (0.06) 0.47 (0.06)
Histidine, mmol/L 0.07 (0.01) 0.07 (0.01) 0.08 (0.01) 0.06 (0.01)
Isoleucine, mmol/L 0.05 (0.02) 0.06 (0.02) 0.05 (0.02) 0.03 (0.01)
Leucine, mmol/L 0.07 (0.02) 0.08 (0.02) 0.06 (0.02) 0.05 (0.01)
Valine, mmol/L 0.16 (0.04) 0.17 (0.04) 0.14 (0.04) 0.14 (0.03)
Phenylalanine, mmol/L 0.07 (0.01) 0.07 (0.01) 0.04 (0.01) 0.04 (0.01)
Tyrosine, mmol/L 0.05 (0.01) 0.05 (0.01) 0.07 (0.02) 0.05 (0.01)
Ketone bodies
Acetate, mmol/L 0.031 (0.005) 0.04 (0.04) 0.058 (0.024) 0.064 (0.028)
Acetoacetate, mmol/L 0.031 (0.018) 0.03 (0.02) 0.053 (0.048) 0.034 (0.026)
3hydroxybutyrate, mmol/L 0.12 (0.09) 0.112 (0.084) 0.07 (0.10) 0.11 (0.12)
Fluid balance
Creatinine, mmol/L 0.040 (0.007) 0.06 (0.01) 0.036 (0.006) 0.062 (0.010)
Albumin (signal area) 0.093 (0.005) 0.09 (0.01) 0.090 (0.004) 0.091 (0.004)
ex.large indicates extra large; HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; polyunsat., polyunsaturated; VLDL, very-low-density
lipoprotein.
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that PWV and cIMT are surrogate measures of atherosclerosis,
whereas the occurrence of cardiovascular events requires both
an underlying atherosclerotic plaque formation and different
factors that lead to plaque instability and rupture.
In contrast to studies of adults both younger and older
than our study population, we found little evidence of
associations between metabolite measures and cIMT in
adults. Speciﬁcally, a study of 1297 participants (mean age,
60 years), focusing on amino acids, found that circulating
tyrosine, phenylalanine, and isoleucine were associated with
cIMT,28 whereas a second NMR-based prospective study
(N=1595; mean age at baseline, 32 years) linked docosahex-
aenoic acid, tyrosine, and glutamine with cIMT progression.29
Replication was not undertaken for either study, but in both
reports, tyrosine was related to subclinical atherosclerosis.
For the lipid measures, in an earlier study utilizing a similar
Figure 2. Correlation between parent and child metabolites. Bars represent Spearman’s correlation coefﬁcients. HDL indicates high-density
lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein.
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NMR-based methodology, several HDL-cholesterol subgroups
and HDL particle size have been shown to predict future lower
risk of cardiovascular events.27 Similar ﬁndings have been
reported on the association with cIMT30 and 6-year intima-
media thickness progression.29 Of those factors previously
associated with cIMT, we observed that tyrosine and
glutamine were associated with PWV among CheckPoint
adults (no PWV data were available in ALSPAC adults).
However, unlike previous associations with cIMT (ie, higher
level of metabolite related with thicker/worse carotid artery
structure),28,29 we found tyrosine and glutamine to be
inversely associated with PWV (ie, higher level of metabolite
Figure 3. Associations between metabolomic measures and carotid intima-media thickness (cIMT) in children and adults. Association
measures are difference in mean cIMT per 1-SD unit increase in metabolite for A) CheckPoint children (blue), CheckPoint adults (red), and B) The
Avon Longitudinal Study of Parents and Children (ALSPAC) mothers (gray) adjusted for age and sex. Error bars represent 95% conﬁdence
intervals (CI). Signiﬁcant associations after P values adjusted for multiple testing using the Benjamini–Hochberg procedure are shown in bold
(false discovery rate=0.10). CHPT indicates Child Health CheckPoint; HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; LDL,
low-density lipoprotein; VLDL, very-low-density lipoprotein.
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was associated with better arterial function). The inverse
association with glutamine is consistent with the previous
meta-analysis of 3 independent cohorts described above,
which found an inverse association with incident CVD.27 In
keeping with earlier studies on cIMT, we observed that HDL-
cholesterol–related measures were inversely associated with
PWV among CheckPoint adults. In previous studies of the
associations between metabolites and PWV, Menni et al31
observed, among 1797 female twins (mean age, 58 years),
that 12 metabolites, including glutamine, were inversely
associated with PWV in BMI-adjusted models. In a case-
control study among males with/without peripheral artery
Figure 4. Associations between metabolomic measures and carotid intima-media thickness (cIMT) in children and adults. Association
measures are difference in mean cIMT per 1-SD unit increase in metabolite for A) CheckPoint children (blue), CheckPoint adults (red), and B) The
Avon Longitudinal Study of Parents and Children (ALSPAC) mothers (gray) adjusted for age, sex, body mass index, and blood pressure. Error bars
represent 95% conﬁdence intervals (CI). Signiﬁcant associations after P values adjusted for multiple testing using the Benjamini–Hochberg
procedure are shown in bold (false discovery rate=0.10). CHPT indicates Child Health CheckPoint; HDL, high-density lipoprotein; IDL,
intermediate-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein.
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disease, tyrosine levels were positively associated with PWV
in the case group.32
There is increasing interest in the utility of the metabo-
lomic proﬁle as a part of clinical risk prediction, particularly in
the primary prevention of CVD. Our ﬁndings from general
populations do not support the introduction of NMR
metabolic proﬁles into pediatric cardiovascular practice.
Among adults, we observed some signals related to preclin-
ical atherosclerosis, but the most robust evidence to date
with this NMR platform comes from prospective analyses with
disease end points and replication across 3 independent
cohorts.27
Figure 5. Associations between metabolomic measures and pulse wave velocity (PWV) in children and adults. Association measures are
difference in PWV per 1-SD unit increase in metabolite concentration for A) CheckPoint children (blue), CheckPoint adults (red), and B) The Avon
Longitudinal Study of Parents and Children (ALSPAC) children (gray) adjusted for age and sex. Error bars represent 95% conﬁdence intervals (CI).
Signiﬁcant associations after P values adjusted for multiple testing using the Benjamini–Hochberg procedure are shown in bold (false discovery
rate=0.10). CHPT indicates Child Health CheckPoint; HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density
lipoprotein; VLDL, very-low-density lipoprotein.
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To our knowledge, this is the ﬁrst study to examine the
metabolomics proﬁle of cardiovascular phenotypes among
children. Importantly, we analyzed data from 2 independent
cohorts that used the same NMR metabolomics platform.
Some limitations to the present study warrant consideration,
particularly the cross-sectional nature of most of the data,
which limits causal inference. The childhood analyses
between CheckPoint and ALSPAC cohorts are not entirely
comparable, given that CheckPoint analyses were cross-
sectional, whereas in the ALSPAC they were prospective. The
lack of any associations in the ALSPAC, even in age- and sex-
adjusted analyses, might imply that the metabolites analyzed
Figure 6. Associations between metabolomic measures and pulse wave velocity (PWV) in children and adults. Association measures are
difference in PWV per 1-SD unit increase in metabolite concentration for A) CheckPoint children (blue), CheckPoint adults (red), and B) The Avon
Longitudinal Study of Parents and Children (ALSPAC) children (gray) adjusted for age, sex, body mass index, and blood pressure. Error bars
represent 95% conﬁdence intervals (CI). Signiﬁcant associations after P values adjusted for multiple testing using the Benjamini–Hochberg
procedure are shown in bold (false discovery rate=0.10). CHPT indicates Child Health CheckPoint; HDL, high-density lipoprotein; IDL,
intermediate-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein.
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are not causally related to subclinical atherosclerosis in
children, but further prospective analyses are warranted.
Neither study had data on the progression of atherosclerotic
phenotypes. The ALSPAC study did not have data on PWV in
adults, nor cIMT in children. In addition, PWV measures
differed between the 2 cohorts (carotid-femoral PWV in
CheckPoint, carotid-radial PWV in the ALSPAC). The adult
participants in both cohorts were not representative of the
general populations given that they largely comprised moth-
ers. We have previously shown that the CheckPoint cohort is
under-represented of socioeconomically disadvantaged fam-
ilies,22 and although ALSPAC reﬂects the sociodeomographic
characteristics of the local (South West of England) population
from which it was drawn, it is more afﬂuent and less ethnically
diverse than the rest of the UK. Thus, results from the adults
in our study may not generalize to men, and in both age
groups may not generalize to non-white European ethnicities
or those from more-deprived socioeconomic backgrounds.
In conclusion, the present data suggest that, among
children, blood metabolites have no independent association
with cIMT and arterial PWV after adjustment for BMI and BP. In
adults, these data suggest that glucose levels are positively and
some HDL-related measures and amino acids inversely asso-
ciated with lower PWV, but this requires further replication.
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